TABLE 3.

Selection of 4 Explant-Based Prognostic Models for LT for HCC

Study	Design	Patients Within the Milan Criteria/Total Patients (n/N)	Follow-Up	Model Components	Proposed Model	Main Results	Level of Evidence*
Mazzaferro et al.29 (2009)	Multicenter, retrospective cohort	1112/1556	53 months (median)	Largest size, number, and microvascular invasion	Up-to-7 criteria (largest size plus number)	5-year overall survival: 71.2% (47.4% with microvascular invasion)	2b/4
Chan et al.41 (2008)	Retrospective cohort with validation	Test cohort: —/116 Validation cohorts: 31 and 41	Test: 27 months Validation: 104 and 28 months (mean)	Largest size (1 point), bilobar distribution (2 points), macrovascular invasion (3 points), and not well differentiated (−3 points)	PCRS	5-year overall survival: 90% with PCRS ≤ 0, 65% with PCRS = 1 or 2, and 20% with PCRS ≥ 3	2b
Parfitt et al.39 (2007)	Retrospective cohort	50/75	8 years (mean)	Microvascular invasion, microsatellitosis, giant/bizarre cells, and largest size ≥ 3 cm	3.5–4 points for each variable	Incidence of recurrence: <5% with 0–4 points, 40%–65% with 7–7.5 points, and >95% with 10.5–14.5 points	2b/4
Iwatsuki et al.37 (2000)	Retrospective cohort	—/344	91 months (mean)	Bilobar distribution, largest size (>2 or 5 cm), and microvascular/ macrovascular invasion	Prognostic risk score (3.1–15.0 points for each variable)	5-year disease-free survival: 100% with <7.5 points, 61% with ≤11.0 points, 40% with <15.0 points, and 5% with ≥15.0 points	2b/4

^*Evidence level 2b is based on clinical decision rules (scoring systems), and evidence level 4 is based on a retrospective study of populations.